Stanton J. Lovenworth

Partner

Stanton J. Lovenworth has more than 30 years of experience in corporate representation, including intellectual property transactions, mergers and acquisitions (M&A) and business organization. He is the chair of the firm’s Life Sciences Global Industry Sector Group and member and former global co-chair of the firm's Technology and Intellectual Practice Group.

Mr. Lovenworth has extensive experience in transactional intellectual property matters, including technology licensing (particularly in the pharmaceutical, biotech and media sectors); patent, trademark, copyright and merchandise licensing; formation of pharmaceutical, biotech and other intellectual property-based or -centered joint ventures, collaborations and strategic alliances; research, development, clinical trial, co-development, co-promotion, and supply and manufacturing agreements in the pharmaceutical and biotech sectors; and “spin-outs” and investment and M&A transactions involving intellectual property assets in a variety of technology and media sectors. In addition, Mr. Lovenworth has broad experience in protection and enforcement of trademark rights, with special emphasis on certification marks and protection of geographic indications.

For transactional intellectual property matters, representative clients include Novartis, Eli Lilly, Actavis, MedImmune, Gilead, Aptalis, Progenics, Illumina, Merz, Medicis, Pronova and Onyx (pharmaceutical and biotechnology mergers and acquisitions, collaborations and licensing); SONY, The Walt Disney Company and Providence Equity (entertainment industry acquisitions and divestitures); The Walt Disney Internet Group (acquisition and sale of Internet search and hosting technology); The National Federation of Coffee Growers of Colombia and Republic of Colombia trademark protection and enforcement); Starbucks Coffee Company (trademark licensing, certification mark matters); and Unilever (integrated marketing matters). Mr. Lovenworth has been recognized in The Legal 500 US in the areas of trademarks every year from 2007 through the present, advertising and marketing (2010 and 2011) and Life Sciences (2011), and as a New York Super Lawyer in 2006, 2007, 2008 and 2009.

Selected Activities

  • American Bar Association, Section of Intellectual Property
  • International Trademark Association
  • Licensing Executives' Society

Publications*

  • "U.S. Supreme Court Hears Arguments in Bayh-Dole Act Case Pitting Rights of Individual Inventors Against Universities," Bloomberg Law Reports (April 2011).
  • "Patent Licensees: Beware Impact of Licensor Bankruptcy," New York Law Journal (June 2010).
  • American Origin Products (AOP): Protecting a Legacy (2010).
  • "Update for Small Biotech and Pharmaceutical Companies," Practical U.S./Domestic Tax Strategies (May 2010).
  • "Protect Your IP Licensing Agreement," Executive Counsel (November 2009).
  • "Protecting Geographically Unique Products," New York Law Journal (January 22, 2008).
  • "Exit via the Pipeline: M&A Activity in the Pharmabiotech Sector," Daily Deal (November 28, 2006).
  • "Welcome to the World of Wiki and Linux: Enforcement of Copyright in Collaborative Works," TMCnet ( September 27, 2006).
  • "The Research Tool Conundrum," New York Law Journal (October 17, 2005).
  • "Merck v. Integra: Its effect on Innovative Drug Discovery," Bio-IT World (August 2, 2005).
  • "The Third Thing: Defining Trade Dress After Wal-Mart v. Samara Brothers," Legal Times (March 4, 2002).
  • "Exploring the Boundaries of Co-Existing Trademarks," New York Law Journal (January 15, 1999).
  • "Planning For A New Age: Employee Ownership of Intellectual Property," The Corporate Counselor (March 1996).
  • "Protection of Well Known Trademarks in China," New York Law Journal (August 21, 1995).
  • "China Trade Accord May Protect Software Vendors," The National Law Journal (June 5, 1995).

* Co-Author

Speeches and Programs

  • AIPPI, "Protecting Geographical Indications in the United States" (Hyderabad, India, October 2011).
  • OriGIn, "GI Challenges in the U.S." (Washington, D.C., June 2010).
  • OriGIn, "GI Challenges in the U.S." (Geneva, Switzerland, February 2010).
  • OriGIn General Assembly, "GI Challenges in the U.S." (Teruel, Spain, June 2009).
  • ABA IP Law Section, "Protecting Geographically Distinctive Products in the United States" (Washington, D.C., April 3, 2009).
  • New York Biotechnology Association, "Innovative Financing Techniques for Pharmas and Biotechs" (New York, February 24, 2009).
  • ACI, "Using Due Diligence to Identify and Minimize Risks" (New York, November 14, 2006).
  • BioNetwork 2006, "Creative New Deal Structures" (Laguna Beach, October 4, 2006).
  • Licensing Executives Society, "Commercial and Ethical Issues in Pandemic Flu Collaboration" (New York, September 13, 2006).
  • New York Biotechnology Association, "Biotech-Pharma Collaborations: The Fiduciary Duties You Owe to Your Collaboration Partners and How to Handle Them" (New York, April 18, 2006).
  • ACI, "Life Sciences IP Due Diligence" (New York, January 31 and June 27, 2006).
  • New York Biotechnology Association, "What You Should Know About Your Fiduciary Duties to Your Partners" (New York, May 25, 2005).
  • BioBusiness 2004, "When Equity Enters the Equation: Examining the Key Governance and Alliance Issues in Pharma/Biotech Deals" (Geneva, January 28, 2004).

Education

  • Columbia University Law School, 1977, JD, Harlan Fiske Stone Scholar
  • Haverford College, 1971, BA, magna cum laude, Phi Beta Kappa, History prize
  • Cambridge University, 1971-1972
  • University of Paris, associated with Ecole Normale Supérieure, 1974, MA, with High Honors

Bar Admissions

  • New York